Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing total lung capacity.

EXCLUSIVE: Generate Biomedicines CTO Gevorg Grigoryan says Nvidia ($NVDA) GPUs are essential for AI drug discovery, but they will not decide the winners. He says the real moat is proprietary biological data, experimentation and feedback loops.

It was great to visit @KuInnovation to see how @UnivOfKansas is connecting students with local job creators to gain early career experience while helping to develop new technologies in industries like cybersecurity and biomedicine. By creating these opportunities right next to campus, students can contribute to the innovation happening in their own communities while helping Kansas can retain its homegrown talent. READ MORE @LJWorld:

How a T cell killing a B cell in a petri dish turns into a strategic collaboration between J&J and #FlagshipFounded# @SailBiomeds to develop in vivo CAR-T: @AvakK, President of Flagship Labs and Co-Founder of Sail Biomedicines, reflects on the origins and potential impact of eRNA-based therapies. Read more here:

Expedition 75 awaits a cargo-packed @SpaceX Dragon on its way for a space delivery on Thursday. Meanwhile, biomedicine and advanced space innovations filled the crew's day on Tuesday. More...

CHINA TECH ORDER BACKLOGS SIGNAL RECOVERY IN KEY SECTORS, WITH ~30 LISTED COMPANIES REPORTING STRONG FIRST-HALF ORDERS. || BIOMEDICINE, NEW ENERGY, SEMICONDUCTORS AND ADVANCED EQUIPMENT LEAD THE IMPROVEMENT, WITH SEVERAL FIRMS REPORTING BACKLOGS ABOVE 5 BILLION YUAN.

Nvidia's 13F dropped Friday. $63.44B across 8 positions. $INTC $29.99B SpaceX $20.98B $CRWV $4.70B $COHR $3.07B $NOK $2.21B $SNPS $2.15B $NBIS $328.8M Generate Biomedicines $14.1M Intel and SpaceX are 80% of the book

Anthropic has acquired Mithril Medicine, a one-person biotech startup, and is now running drug discovery programs of its own. Founder Cody Tranbarger used Claude to coordinate contracts, logistics and experiments with 11 external labs. Anthropic says that work took a potential treatment for a rare form of muscular dystrophy from an idea to promising results in mice in under 18 months. Mithril has been developing treatments for two rare forms of muscular dystrophy. Tranbarger is continuing the research at Anthropic, which says a drug could be ready to start human trials as early as late 2028 if the candidates continue to hold up. Anthropic also announced research partnerships with six organizations, including Bristol Myers Squibb, Generate Biomedicines and Enveda. The work spans drug design, manufacturing, regulatory documentation and clinical trial planning. Most of the research remains preclinical. The broader goal is to use Claude across the scientific and operational work required to move a potential medicine toward patients.

📢 𝗝𝗨𝗦𝗧 𝗜𝗡: Anthropic Partners With Six Life Sciences Firms to Accelerate AI-Powered Drug Development - $ANT $BMY 👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ➤ 𝗔𝗻𝘁𝗵𝗿𝗼𝗽𝗶𝗰 partners with 𝟲 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 organizations to test Claude. ➤ Partners include 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯, 𝗕𝗶𝗴𝗛𝗮𝘁, 𝗘𝗻𝘃𝗲𝗱𝗮, 𝗗𝗶𝘃𝗲𝗿𝗴𝗲𝗻𝗰𝗲, 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗲, and 𝗧𝗵𝗲 𝗖𝗼𝗹𝘂𝗺𝗻 𝗚𝗿𝗼𝘂𝗽. ➤ 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗲 𝗕𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 designed a 𝟳𝟬% 𝘀𝗵𝗼𝗿𝘁𝗲𝗿 CAR T-cell component using Claude. ➤ Modified design produced approximately 𝟭𝟬𝘅 𝗺𝗼𝗿𝗲 cancer-targeting receptors in lab tests. ➤ 𝗗𝗶𝘃𝗲𝗿𝗴𝗲𝗻𝗰𝗲 𝗟𝗮𝗯𝘀 generated approximately 𝟯𝟱,𝟬𝟬𝟬 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗱𝗲𝘀𝗶𝗴𝗻𝘀 in one month. ➤ 𝗘𝗻𝘃𝗲𝗱𝗮 used Claude to review 𝟭,𝟬𝟲𝟭 𝗽𝗮𝗴𝗲𝘀 of manufacturing documentation. ➤ Claude identified 𝟭𝟭 𝗸𝗻𝗼𝘄𝗻 𝗶𝘀𝘀𝘂𝗲𝘀 plus 𝟳 𝗮𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗶𝘀𝘀𝘂𝗲𝘀, reducing review time 𝟴𝟵%. ➤ Claude drafted a regulatory document in 𝟰 𝗵𝗼𝘂𝗿𝘀 versus approximately 𝟯 𝗺𝗼𝗻𝘁𝗵𝘀. ➤ 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯 uses Claude for clinical trial planning and success estimates. ➤ Anthropic acquired 𝗠𝗶𝘁𝗵𝗿𝗶𝗹 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 and launched 𝗖𝗹𝗮𝘂𝗱𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲. 👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: ➤ Demonstrates AI's potential to 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 and reduce development costs. ➤ Significant efficiency gains could transform 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 and regulatory workflows. ➤ Partnerships position 𝗔𝗻𝘁𝗵𝗿𝗼𝗽𝗶𝗰 to expand into the high-value 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗔𝗜 market. ➤ 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯 (𝗕𝗠𝗬) gains AI-assisted clinical development capabilities. ➤ Early laboratory results remain preliminary and require 𝗳𝘂𝗿𝘁𝗵𝗲𝗿 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 before clinical use. 👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁: 𝗠𝗶𝗰𝗵𝗮𝗲𝗹 𝗣𝗼𝘂𝗿𝗱𝗲𝗵𝗻𝗮𝗱, Senior Vice President and Head of Early Clinical Development at Bristol Myers Squibb: "generated a robust initial analysis that helped inform our assessment of different development options, which would otherwise take days to complete."